Chronic Kidney Disease With Albuminuria In Type 2 Diabetes Therapeutics
1. Kerendia patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE49826 | BAYER HLTHCARE | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
Jul, 2035
(9 years from now) | |
| US8436180 | BAYER HLTHCARE | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-279) | Sep 01, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 09, 2026 |
| New Indication(I-970) | Jul 11, 2028 |
| New Strength(NS) | Jul 11, 2028 |
Drugs and Companies using FINERENONE ingredient
NCE-1 date: 09 July, 2025
Market Authorisation Date: 09 July, 2021
Dosage: TABLET
More Information on Dosage
KERENDIA family patents
